HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Approved and Investigational SERDs in HR+/HER2– Breast Cancer

January 23rd 2025

Dr. Gandhi and Dr. Clifton discuss the evolving role of oral selective estrogen receptor degraders (SERDs) in the treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer, considering patient characteristics, clinical scenarios, and the landscape of approved and investigational agents, including elacestrant, imlunestrant, and camizestrant.

Endocrine Sensitivity and the Prognostic and Clinical Implications

January 23rd 2025

Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.

SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors

January 22nd 2025

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer

January 22nd 2025

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes

January 17th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer

January 17th 2025

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

January 15th 2025

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

January 15th 2025

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Dr Montero on Zanidatamab and Evorpacept in HER2-Expressing Metastatic Breast Cancer

January 15th 2025

Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer

January 15th 2025

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

January 14th 2025

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer

January 9th 2025

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Dr Li on Neoadjuvant SHR-A1811 in HER2+ Breast Cancer

January 3rd 2025

Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases

December 13th 2024

T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

December 12th 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer

December 5th 2024

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.

Disitamab Vedotin Shows Early Efficacy in HER2-Expressing Breast Cancer With PAM Pathway Abnormalities

December 4th 2024

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast Cancer

November 27th 2024

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.